188 related articles for article (PubMed ID: 7729921)
1. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice.
Wilson ME; Young BM; Andersen KP; Weinstock JV; Metwali A; Ali KM; Donelson JE
Infect Immun; 1995 May; 63(5):2062-9. PubMed ID: 7729921
[TBL] [Abstract][Full Text] [Related]
2. BCG expressing LCR1 of Leishmania chagasi induces protective immunity in susceptible mice.
Streit JA; Recker TJ; Donelson JE; Wilson ME
Exp Parasitol; 2000 Jan; 94(1):33-41. PubMed ID: 10631078
[TBL] [Abstract][Full Text] [Related]
3. Leishmania chagasi T-cell antigens identified through a double library screen.
Martins DR; Jeronimo SM; Donelson JE; Wilson ME
Infect Immun; 2006 Dec; 74(12):6940-8. PubMed ID: 17000724
[TBL] [Abstract][Full Text] [Related]
4. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-gamma production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge.
Marques-da-Silva EA; Coelho EA; Gomes DC; Vilela MC; Masioli CZ; Tavares CA; Fernandes AP; Afonso LC; Rezende SA
Parasitol Res; 2005 Dec; 98(1):67-74. PubMed ID: 16261353
[TBL] [Abstract][Full Text] [Related]
5. Identification and molecular characterization of a gene encoding a protective Leishmania amazonensis Trp-Asp (WD) protein.
Campbell K; Popov V; Soong L
Infect Immun; 2004 Apr; 72(4):2194-202. PubMed ID: 15039343
[TBL] [Abstract][Full Text] [Related]
6. New Vaccine Formulations Containing a Modified Version of the Amastigote 2 Antigen and the Non-Virulent
Almeida APMM; Machado LFM; Doro D; Nascimento FC; Damasceno L; Gazzinelli RT; Fernandes AP; Junqueira C
Front Immunol; 2018; 9():465. PubMed ID: 29599776
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
Stäger S; Smith DF; Kaye PM
J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis.
Burns JM; Shreffler WG; Benson DR; Ghalib HW; Badaro R; Reed SG
Proc Natl Acad Sci U S A; 1993 Jan; 90(2):775-9. PubMed ID: 8421715
[TBL] [Abstract][Full Text] [Related]
10. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
11. Complete conservation of an immunogenic gene (lcr1) in Leishmania infantum and Leishmania chagasi isolated from Iran, Spain and Brazil.
Mahmoudzadeh-Niknam H; Abrishami F; Doroudian M; Moradi M; Alimohammadian MH; Parvizi P
J Vector Borne Dis; 2010 Dec; 47(4):204-10. PubMed ID: 21178212
[TBL] [Abstract][Full Text] [Related]
12. Antigens shared by Leishmania species and Trypanosoma cruzi: immunological comparison of the acidic ribosomal P0 proteins.
Skeiky YA; Benson DR; Elwasila M; Badaro R; Burns JM; Reed SG
Infect Immun; 1994 May; 62(5):1643-51. PubMed ID: 7513304
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
[TBL] [Abstract][Full Text] [Related]
14. A Leishmania amastigote-specific hypothetical protein evaluated as recombinant protein plus Th1 adjuvant or DNA plasmid-based vaccine to protect against visceral leishmaniasis.
Oliveira-da-Silva JA; Machado AS; Ramos FF; Tavares GSV; Lage DP; Mendonça DVC; Pereira IAG; Santos TTO; Martins VT; Carvalho LM; Freitas CS; Ludolf F; Reis TAR; Bandeira RS; Silva AM; Costa LE; Oliveira JS; Duarte MC; Roatt BM; Teixeira AL; Coelho EAF
Cell Immunol; 2020 Oct; 356():104194. PubMed ID: 32827943
[TBL] [Abstract][Full Text] [Related]
15. Immunization with the cysteine proteinase Ldccys1 gene from Leishmania (Leishmania) chagasi and the recombinant Ldccys1 protein elicits protective immune responses in a murine model of visceral leishmaniasis.
Ferreira JH; Gentil LG; Dias SS; Fedeli CE; Katz S; Barbiéri CL
Vaccine; 2008 Jan; 26(5):677-85. PubMed ID: 18160187
[TBL] [Abstract][Full Text] [Related]
16. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
Daifalla NS; Bayih AG; Gedamu L
Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
[TBL] [Abstract][Full Text] [Related]
17. Cloning, characterization and serological evaluation of K9 and K26: two related hydrophilic antigens of Leishmania chagasi.
Bhatia A; Daifalla NS; Jen S; Badaro R; Reed SG; Skeiky YA
Mol Biochem Parasitol; 1999 Aug; 102(2):249-61. PubMed ID: 10498181
[TBL] [Abstract][Full Text] [Related]
18. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis.
Webb JR; Kaufmann D; Campos-Neto A; Reed SG
J Immunol; 1996 Dec; 157(11):5034-41. PubMed ID: 8943412
[TBL] [Abstract][Full Text] [Related]
19. Cellular and humoral immunity to Leishmania major in genetically susceptible mice after in vivo depletion of L3T4+ T cells.
Sadick MD; Heinzel FP; Shigekane VM; Fisher WL; Locksley RM
J Immunol; 1987 Aug; 139(4):1303-9. PubMed ID: 3112230
[TBL] [Abstract][Full Text] [Related]
20. Peripheral expression of LACK-mRNA induced by intranasal vaccination with PCI-NEO-LACK defines the protection duration against murine visceral leishmaniasis.
De Oliveira Gomes DC; Schwedersky RP; Barbosa De-Melo LD; Da Silva Costa Souza BL; De Matos Guedes HL; Lopes UG; Rossi-Bergmann B
Parasitology; 2012 Oct; 139(12):1562-9. PubMed ID: 23036534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
